4BB 4basebio Plc

 
TIDM4BB 
 
1 August 2023 
 
4basebio PLC 
 
("4basebio", the "Company" or the "Group") 
 
4basebio receives grant to advance its synthetic DNA platform and HermesT 
nanoparticle platform for the development of 
thermostable nucleic acid vaccines 
 
  · Funding from the Bill & Melinda Gates Foundation will build on preclinical 
data demonstrating superior immune responses achieved with 4basebio's synthetic 
DNA products as well as improved stability offered by its HermesT platform. 
 
Cambridge, UK, 1 August 2023 - 4basebio PLC (AIM: 4BB), an innovation driven 
biotechnology company enabling and accelerating development of advanced therapy 
medicinal products (ATMPs) through its high performant synthetic DNA products 
and non-viral, thermostable nucleic acid delivery platform, today announces it 
has received a grant from the Bill & Melinda Gates Foundation (the "Foundation") 
to advance the development program of thermostable nucleic acid based vaccines. 
 
The development program aims to build on preclinical data demonstrating the 
improved stability offered by the HermesT platform, the superior immune 
responses achieved with 4basebio's synthetic DNA products and high-quality mRNA 
produced from 4basebio opDNAT products. 
 
The successful demonstration of the HermesT platform and 4basebio synthetic 
nucleic acid payloads in infectious disease vaccines has the potential to 
enhance the global availability of such innovative medicines. 
 
Heikki Lanckriet, CEO and CSO of 4basebio, commented: "The Foundation's grant 
recognises the potential of our HermesT and synthetic DNA platforms. The 
enhanced stability offered by our vectors as well as the rapid turnaround time 
offered through our synthetic DNA has the potential to enable a faster response 
to pandemic needs and create highly performant and affordable vaccine products 
in support of the global fight against infectious diseases." 
 
For further enquiries, please contact: 
 
4basebio PLC 
                                  +44 (0)12 2396 7943 
 
Heikki Lanckriet 
 
Nominated Adviser                                                            +44 
(0)20 7213 0880 
 
Cairn Financial Advisers LLP 
 
Jo Tuner / Sandy Jamieson 
 
Broker 
                  +44 (0)20 7220 0500 
 
finnCap Ltd 
 
Geoff Nash/Richard Chambers/Charlotte Sutcliffe 
 
Lionsgate Communications (Media Enquiries)                 +44 (0)77 91892509 
Jonathan Charles 
 
Notes to Editors 
 
About 4basebio 
 
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focussed 
on accelerating the development of advanced therapy medicinal products (ATMPs) 
through its high performant synthetic DNA products and non-viral, cell targeting 
nucleic acid delivery platform. The Company's objective is to become a market 
leader in the manufacture and supply of high quality synthetic DNA products for 
research, therapeutic and pharmacological use as well as development of target 
specific non-viral vectors for the efficient delivery of payloads in patients. 
The Company is offering GMP compliant DNA starting materials suitable for use in 
AAV viral vector production as well as mRNA vaccine and therapeutics production. 
 
Forward-looking statements 
 
This announcement may contain certain statements about the future outlook for 
the 4basebio.  Although the directors believe their expectations are based on 
reasonable assumptions, any statements about future outlook may be influenced by 
factors that could cause actual outcomes and results to be materially different. 
 
 
This information was brought to you by Cision http://news.cision.com 
 
 
END 
 
 

(END) Dow Jones Newswires

August 01, 2023 02:00 ET (06:00 GMT)

Grafico Azioni 4basebio (LSE:4BB)
Storico
Da Gen 2025 a Feb 2025

Grafico Azioni 4basebio (LSE:4BB)
Storico
Da Feb 2024 a Feb 2025